Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (January 2025)
15 slides from Enveric Biosciences's investor presentation, January 2025
Slide 1: Corporate Presentation Q1 2025
:ENVB CORPORATE PRESENTATION Q1 2025 Enveric.com
Slide 2: Disclaimer
Disclaimer No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectu
Slide 3: Next Generation Mental Health
Next Generation TM Mental Health
Slide 4: Significant Global Health Issues: Depression, Anxiety & PTSD
Significant Global Health Issues: Depression, Anxiety & PTSD WIDESPREAD LOW EFFICACY 65 million in the US 40% 1 billion globally Experience a neuropsychiatric First line SSRI treatments work disorder at some time in their lives for less than half of patients Source: (NIMH) (SingleCare) (World Heal
Slide 5: Neuroplastogens: A New Class of Drugs
Neuroplastogens: A New Class of Drugs Prefrontal Cortex Healthy Brain: Neurons in the prefrontal cortex (PFC) regulate emotional behavior via Top-Down control of the amygdala. Neuroplastogens stimulate Neuropsychiatric Illness: Reduced neuroplasticity in the PFC, which restores This modulates the fi
Slide 6: Psychedelic Neuroplastogen Drawbacks
Psychedelic Neuroplastogen Drawbacks: • Current neuroplastogens in clinical trials cause hallucinations in the patient • Require 8 hrs in-clinic treatment with two healthcare providers present, plus pre and post treatment counselling • Require psychotherapy as part of the treatment paradigm • Expens
Slide 7: EB-003: Non-Hallucinogenic Neuroplastogen Discovered in 1,000+ Molecule Library
EB-003: Non-Hallucinogenic O F Neuroplastogen Discovered in 1,000+ Molecule Library • Integrated synthetic biology and chemistry to create new library F F • Designed molecules based on natural serotonin receptor ligands HO F CI • Screened for appropriate receptor engagement, efficacy models, and saf
Slide 8: EB-003: A New Treatment Standard
EB-003: A New Treatment Standard Approved Psychedelic Targeted Benefits* Antidepressants Neuroplastogens For EB-003 Immediate efficacy Low side effects Treatment in-clinic not required Large patient population Induces neuroplasticity in brain * To be proven in human clinical trials :ENVB
Slide 9: EB-003: Development Underway
EB-003: Development Underway Synopsis of Target Benefits • Reduced hallucination profile, treatment in clinic not required • Lower side effects • Rapid acting • Orally bioavailable • Intended to be prescribed for regular maintenance and taken at times and in settings convenient to patient 2025 2026
Slide 10: Market Potential: Redefining the Treatment Landscape for Mental Health Disorders
Market Potential: Redefining the Treatment Landscape for Mental Health Disorders Current Approved Predicted Neuroplastogen Antidepressant Market: EB-003: A Breakthrough Market: Neuroplastogen $20 Billion $35.4 Billion Neuroplastogen drug market anticipated by 2030 Leading Neuroplastogen Source: Cohe
Slide 11: Additional Assets Leveraged from Discovery Platform
:ENVB Additional Assets Leveraged from Discovery Platform • Portfolio of 1,000+ novel drug candidates • 23 issued patents & 60 pending patent applications • Numerous distinct assets available for partnering or out- licensing • Multiple future revenue streams possible :ENVB
Slide 12: Product Pipeline
Product Pipeline Partner / Licensee Discovery Pre-Clinical IND Phase 1 Available for Partnering Partner EB-003 Available Out-Licensed Licensee EB-002 & EVM201 MycoMedica Life Sciences Topical Product for Radiation Aries Science & Technology Dermatitis :ENVB
Slide 13: Management
Management Management Team Board of Directors Scientific Advisors Joseph Tucker, Ph.D. Michael D. Webb Maurizio Fava, M.D. Chief Executive Officer Board Chair Scientific Advisor & Director George Kegler Stephen M. Stahl, M.D. Director, Chair of the Audit Committee Scientific Advisor Kevin Coveney, C
Slide 14: Potential First in Class Entrant to Large Mental Health Market
Potential First in Class Entrant to Large Mental Health Market EB-003: A Paradigm Shifting Drug Candidate • EB-003 is one of the leading neuroplastogen drug candidates • Anticipate filing IND in Q1 of 2026 and Phase I start in Q2 2026 New Drug Class Market Opportunity • A $35.4 billion market awaits
Slide 15: Enveric Biosciences
Nasdag :ENVB ENVERICG MH renter fearen= Mental Health™ BIOS CIENCES Enveric.com
Enveric Biosciences — Investor Presentation (January 2025) on 6ix